What is claimed is:

10

- 1. A peptide having any one of the sequences SEQ ID NO.1 to SEQ ID NO.8 or a peptide having a sequence derived from any one of the sequences SEQ ID NO.1 to SEQ ID NO.8 by substitution, deletion or addition of one or several amino acids therein and having an osteogenetic activity.
- 2. A peptide according to claim 1 having any one of the sequences SEQ ID NO.9 and SEQ ID No.10 which belong to SEQ ID NO. 1 and the sequence SEQ ID NO.11 which belongs to SEQ ID NO.8.
- 3. An osteogenetic accelerator containing a peptide as set forth in claim 1 as an active ingredient.
- 4. An osteogenetic accelerator according to claim
 3, wherein the peptide is fixed to a carrier.
- 5. An osteogenetic accelerator according to claim 4, wherein the carrier is a ceramics, an artificial bone, a covalently crosslinked gel of alginate or a gel of collagen, hyaluronic acid, calcium sulfate, polylactic acid, polyglycolic acid, hydroxyapatite, tricalcium phosphate, starch, chitin/chitosan, agarose or dextran.
 - 6. An osteogenetic accelerator according to claim
 4 or 5 which contains 0.01 to 50 parts by weight of the
 peptide with respect to 100 parts by weight of the carrier.
- 7. An osteogenetic accelerator according to claim 25 3, wherein the peptide is mixed with, dissolved in or

suspended in an aqueous solvent.

- 8. An osteogenetic accelerator according to claim
 7, wherein the aqueous solvent is physiological saline
 or a physiologically acceptable aqueous solution of
 mannitol, sucrose, lactose, maltose, glucose or fructose.
- 9. An osteogenetic accelerator according to claim 7 or 8, wherein the concentration of the peptide is 0.001% to 5% with respect to the aqueous solvent.
- 10. An osteogenetic accelerator as set forth in claim
 10 3 which is used for treating a bone fracture and for inhibiting decrease in bone substance.
 - 11. Use of a peptide as set forth in claim 1 for the preparation of an osteogenetic accelerator.